A Review of Novel Systemic Therapies and Brain Radiosurgery for Metastatic Melanoma

Dexter A Overbay, Hakan Kaya, Wayne T Lamoreaux, Robert K Fairbanks, Alexander R Mackay, John J Demakas, Barton S Cook, Christopher M Lee

Abstract

Melanoma is a prevalent and particularly aggressive form of skin cancer. Although local disease can be treated well with excision, metastatic extracranial and intracranial disease can be very difficult to treat. Systemic therapies for melanoma have only recently led to statistically significant increases in overall survival with drugs such as Ipilimumab and Vemurafenib. Additionally, melanoma has been classically described as a relatively radio-resistant malignancy. Because of the potential radio-resistance, stereotactic radiosurgery has been widely utilized for intracranial brain metastases and clinical data has revealed excellent rates of local tumor control and tolerability with these highly focused radiation doses.

Keywords: Hernia repair; Giant ventral hernia; Polypropylene mesh

Introduction

There are approximately 68,100 new cases of melanoma diagnosed in the United States each year and 8,700 deaths each year from this disease [1]. Metastatic melanoma has always been a challenging disease for the clinician due to poor treatment options and the aggressive nature of this cancer. While the traditional combination of biologic and cytotoxic agents have been shown to have an increase in relapse-free survival, the data has not shown a robust long-term increase in overall survival with metastatic disease [2-5].

Until recently, only three drugs had been approved by FDA in treatment of melanoma in more than 35 years. These included approval of dacarbazine in 1975 for metastatic melanoma, approval of high dose interferon in 1995 for adjuvant therapy, and approval of high dose interleukin-2 in 1998 for treatment of metastatic melanoma. Following this 35 year period, in 2011 two novel drugs were approved by FDA in treatment of melanoma. Ipilimumab (anti-CTLA4 antibody) and Vemurafenib (V600 mutant BRAF inhibitor) were approved for systemic treatment of metastatic melanoma. Among the older drugs (Dacarbazine, high dose interferon and high dose IL-2), only high dose IL-2 was shown in the past to have a proven impact on overall survival [6-8].

Melanoma also has a predilection to metastasize to the brain and is the third most common cancer to do so [9]. While the reported rates of metastasis to the brain vary widely in the literature (20-40%), autopsy reports of patient with metastatic melanoma reveal the prevalence in some studies to be 75% [10-14]. It is inarguably significant and associated with a high rate of mortality. The median survival of patients with brain metastases who were treated with past therapies was on average two to four months [13, 15, 16]. Interestingly, only 40% of patients with brain metastases secondary to melanoma have a solitary mass [14]. The conventional treatment of choice for brain metastases has been surgical removal, however most brain metastases are not amenable to surgical removal with only approximately 19% of patients being candidates for surgical resection [14] Furthermore, the vast majority of mortality attributable to metastatic melanoma is due to brain metastases [14]. Thus, research into treatment advances such as stereotactic radiosurgery has led to improved intracranial local-control rates and survival for this challenging patient population. This emphasizes the need for novel systemic therapies and intracranial treatments with increased efficacy for metastatic melanoma.
Discussion

The historic first line therapy for metastatic melanoma in patients with good organ function and performance status is Interleukin 2. Interleukin 2 is a cytokine that is an immune signaling agent that stimulates proliferation and differentiation of T cells. By giving high dose Interleukin 2 it is theorized that it stimulates an immune response against melanoma cells. High dose Interleukin 2 therapy has been shown to have better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].

Ipilimumab was approved by the FDA for treatment of metastatic melanoma in March of 2011. It mechanistically binds to the CTLA-4 (cytotoxic T lymphocyte associated antigen 4) molecule on cytotoxic T lymphocytes. By binding to this molecule T lymphocyte activity is increased against melanoma cells. In the first published randomized clinical trial (RCT), ipilimumab, in combination with gp100 or alone, had significantly better response rates than dacarbazine [6]. While Interleukin 2 has similar clinical tumor response rates as chemotherapy, it has shown to significantly improve survival while standard chemotherapy hasn’t [6]. Interleukin 2 therapy, however, can be significantly toxic. Side effects ranged from cardiac, pulmonary, hepatic, and infection. Hypotension was the most common side effect occurring in 64% of patients. Clinical reports revealed that 2.2% of patients died from adverse effects [6].
example, 201 beams are used to converge on the tumor to deposit a large volume of radiation but relatively sparing the surrounding normal tissue.

Multiple trials have been conducted that find SRS prolonging survival in patients with melanoma brain metastases from 2 to 4 months with conventional therapies to 7 to 8 months [22-25]. However, the addition of WBRT after SRS in some studies has been shown to decrease the rate of new brain metastases better than SRS alone. In one RCT, SRS plus WBRT had a 12 month recurrence rate of brain metastases of 46.8% while SRS alone had a recurrence rate of 76.4% [23]. SRS also has been shown to improve quality of life by decreasing headaches, visual disturbances, and seizures [26]. While melanoma is historically thought to be a relatively radio-resistant tumor type, the reported local control rates with SRS range from 75-97%. Furthermore, a large cost-effectiveness and cost-utility analysis done seems to favor radiosurgery as the most cost-effective treatment for any single-brain metastasis [27]. It should also be noted that ipilimumab and vemurafenib have also been shown in clinical trials to have activity against brain metastases by reducing tumor size [28-30].

To summarize, these novel treatments for metastatic melanoma led to improved survival rates and intracranial brain metastasis control, however the disadvantages must be addressed as well. Interleukin 2 can only be used for carefully selected patients who have good organ reserve and performance status and has significant systemic toxicities [6]. Ipilimumab has serious autoimmune toxicity related to it and it takes months to see any clinical response, therefore making a poor choice in patients with large tumor burden. Vemurafenib has a response rate of 40-50% and a clinical effect can be seen in days to weeks, however the duration of response is only 5 - 6 months which is due to either another surface protein mutating creating an alternate pathway, or another protein in the BRAF pathway mutating rendering vemurafenib ineffective [19-20]. Although in general well tolerated, SRS has a small risk of familiar radiation adverse effects such as nausea, hair loss, tissue edema, or brain injury.

Oncologists remain optimistic about the future of metastatic melanoma research. There are currently multiple drugs in phase II and III trials that show promise in the treatment of this disease. Nilotinib, a cKIT inhibitor, has already been approved for use in CML, but is currently being studied for use in melanoma. Dabrafenib, another BRAF inhibitor similar to vemurafenib is under study as well. Allovecod-7 is a drug that incorporates a major histocompatibility complex 1 into the tumor cells allowing the immune system to recognize the tumor cells and attack. These are just a few of the novel drugs that are in development and which show promise.

Conclusion

Due to the addition of novel systemic therapies and advance-
ments in brain radiosurgery for metastatic melanoma, survival and local control rates have been significantly increased. These new discoveries are stepping-stones for new research into more targeted therapies for this aggressive malignancy. Currently, research teams are looking into new mutations in melanoma cells to create novel targeted therapies that will be more efficacious and safer to use. In the meantime, patients with metastatic melanoma should be evaluated for the optimal available treatment and if available invited to participate in open clinical trials. Given the available data, interleukin 2, ipilimumab and vemurafenib should be considered in each patient with metastatic melanoma. For patients with brain metastases, stereotactic radiosurgery with or without whole brain-radiation therapy should always be considered as well.

References

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol. 2007;25(34):5426-5434.
3. Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008;26(35):5748-5754.
4. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17.
5. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18(12):2444-2458.
6. Rosenberg SA, Yang JC, Topalian SL, Schwartzzenbur DJ, Weber JS, Parkinson DR, Seipp CA, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271(12):907-913.
7. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.
8. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-
dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:S11-14.

9. Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7(3):337-344.

10. Bullard DE, Cox EB, Seigler HF. Central nervous system metastases in malignant melanoma. Neurosurgery. 1981;8(1):26-30.

11. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer. 1978;42(2):660-668.

12. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135(6):807-810.

13. Retsas S, Gershuny AR. Central nervous system involvement in malignant melanoma. Cancer. 1988;61(9):1926-1934.

14. Sampson JH, Carter JH, Jr., Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg. 1998;88(1):11-20.

15. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687-1696.

16. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer. 2010;102(8):1213-1218.

17. Hodis FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.

18. Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, Lebbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.

19. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.

20. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.

21. Selek U, Chang EL, Hassenbusch SJ, 3rd, Shiu AS, Lang FF, Allen P, Weinberg J, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys. 2004;59(4):1097-1106.

22. Elaimy AL, Mackay AR, Lamoreaux WT, Fairbanks RK, Demakas JJ, Cooke BS, Peressini BJ, et al. Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients. World J Surg Oncol. 2011;9:69.

23. Mori Y, Kondziolka D, Flickinger JC, Kirkwood JM, Agarwala S, Lunsford LD. Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys. 1998;42(3):581-589.

24. Yu C, Chen JC, Apuzzo ML, O’Day S, Giannotta SL, Weber JS, Petrovich Z. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys. 2002;52(5):1277-1287.

25. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjo M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483-2491.

26. Radbill AE, Fiveash JF, Falkenberg ET, Guthrie BL, Young PE, Meleth S, Markert JM. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer. 2004;101(4):825-833.

27. Mehta M, Noyes W, Craig B, Lamond J, AucHer R, French M, Johnson M, et al. A cost-effectiveness and cost-utility analysis of radiosurgery vs. resection for single-brain metastases. Int J Radiat Oncol Biol Phys. 1997;39(2):445-454.

28. Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res. 2011;21(6):530-534.

29. Margolin KA, Di Giacomo AM, Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol. 2010;37(5):468-472.

30. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.